Literature DB >> 9972509

Recent developments in the management of retinoblastoma.

C L Shields1, J A Shields.   

Abstract

The management of retinoblastoma has gradually changed over the past few decades. There is a trend away from enucleation and external beam radiotherapy toward focal conservative treatments. This is primarily because of earlier detection of the disease and more focused treatment modalities. Enucleation is still employed for retinoblastoma that fills most of the eye, especially when there is a concern for tumor invasion into the optic nerve or choroid. After enucleation, an integrated orbital implant, provides improved motility and appearance of the prosthesis. External beam radiotherapy continues to be an important method of treating less advanced retinoblastoma, especially when there is diffuse vitreous or subretinal seeding. Plaque radiotherapy is useful for controlling small- to medium-sized retinoblastomas, even those with focal vitreous seeds. Tumors that recur after failure of other methods are often suitable for plaque treatment. When plaque radiotherapy is employed in a child receiving chemotherapy, eventual radiation retinopathy can occur. Cryotherapy and photocoagulation provide excellent control of selected small tumors. Advanced laser delivery systems, particularly those that have been adapted to the indirect ophthalmoscope, have facilitated the visualization for treatment of tumors. Thermotherapy is the newest focal method for retinoblastoma. When combined with chemotherapy, thermotherapy provides satisfactory tumor control, leaving the child with a reasonably small scar, thus preserving more vision. Chemoreduction, using intravenous or subconjunctival routes, is often employed to reduce initial tumor volume and thus allow for focal treatment to eradicate the residual smaller tumor. Many children with advanced retinoblastoma can be spared external beam radiotherapy and enucleation mostly as a result of chemoreduction and focal methods. Chemoreduction combined with cryotherapy, thermotherapy, and plaque radiotherapy plays an important role in the current management of many children with retinoblastoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9972509     DOI: 10.3928/0191-3913-19990101-04

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  18 in total

Review 1.  Chemotherapy for retinoblastoma: a current topic.

Authors:  P T Finger; G Czechonska; H Demirci; A Rausen
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  [Vitreous hemorrhage and macular edema with loss of vision].

Authors:  C W Spraul; G E Lang
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

3.  Clinical presentation of retinoblastoma in Malaysia: a review of 64 patients.

Authors:  S C Reddy; S Anusya
Journal:  Int J Ophthalmol       Date:  2010-03-18       Impact factor: 1.779

4.  Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?

Authors:  D S Gombos; P A Cauchi; J L Hungerford; P Addison; P G Coen; J E Kingston
Journal:  Br J Ophthalmol       Date:  2006-05-17       Impact factor: 4.638

5.  Evaluation of high-risk features of primary enucleation of patients with retinoblastoma in a tertiary center of a developing country in the era of intra-arterial chemotherapy.

Authors:  Funda Dikkaya; Ahmet Murat Sarıcı; Firuze Erbek; Tiraje Celkan; Mehmet Serhat Mangan; Övgü Aydın; Cuyan Demirkesen; Halit Pazarlı
Journal:  Int Ophthalmol       Date:  2017-01-05       Impact factor: 2.031

6.  Eye-preserving therapy in retinoblastoma: prolonged primary chemotherapy alone or combined with local therapy.

Authors:  Joo Young Shin; Jeong Hun Kim; Young Suk Yu; Sang In Khwarg; Ho Kyung Choung; Hee Young Shin; Hyo Seop Ahn
Journal:  Korean J Ophthalmol       Date:  2010-08-03

7.  Chemoreduction for retinoblastoma: analysis of tumor control and risks for recurrence in 457 tumors.

Authors:  Carol L Shields; Arman Mashayekhi; Jacqueline Cater; Abdallah Shelil; Anna T Meadows; Jerry A Shields
Journal:  Trans Am Ophthalmol Soc       Date:  2004

8.  Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway.

Authors:  Pina Fortunato; Serena Pillozzi; Angela Tamburini; Liliana Pollazzi; Alessandro Franchi; Agostino La Torre; Annarosa Arcangeli
Journal:  BMC Cancer       Date:  2010-09-22       Impact factor: 4.430

9.  Treatment of retinoblastoma: current status and future perspectives.

Authors:  Carlos Rodriguez-Galindo; Guillermo L Chantada; Barrett G Haik; Matthew W Wilson
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

10.  Expression and amplification of therapeutic target genes in retinoblastoma.

Authors:  Doris Bösch; Mona Pache; Ronald Simon; Peter Schraml; Katharina Glatz; Martina Mirlacher; Josef Flammer; Guido Sauter; Peter Meyer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-11-10       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.